AI-Powered app could help diabetics predict blood sugar and dose insulin smarter

NCT ID NCT07304778

Recruiting now Disease control Sponsor: Universidad Complutense de Madrid Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a mobile app called glUCModel that uses artificial intelligence to predict glucose levels and help people with type 1 diabetes decide how much insulin to take. About 34 adults aged 18 to 65 will use the app for several weeks while wearing a continuous glucose monitor. The main goal is to see if the app helps them keep their blood sugar in a healthy range more often and reduces dangerous highs and lows.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: glUCModel mobile app (AI-powered decision support system)
What this could lead to: If it works, this could give people with type 1 diabetes a smarter tool to manage their insulin doses and reduce dangerous blood sugar swings.
What could go wrong: This is a small early trial with only 34 people, so results may not apply to everyone. The app is a support tool, not a cure, and its benefits may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES (INSULIN-REQUIRING, TYPE 1 OR TYPE 2) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES (INSULIN-REQUIRING, TYPE 1 OR TYPE 2)

Contacts and locations

Locations

Hospital Universitario de Toledo
RECRUITING

Toledo, Toledo, 45007, Spain
Universidad Complutense de Madrid
NOT_YET_RECRUITING

Madrid, Madrid, 280240, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.